Credit Suisse analyst A.J. Rice downgraded CVS Health to Neutral from Outperform after assuming coverage of the name as the stock faces a transitional year as it tries to drive seismic changes in healthcare. While the analyst acknowledged that the stock discounts many of the headwinds CVS faces, he is looking for visibility on earnings growth to improve. Rice also lowered his price target on the shares to $61 from $73.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.